Viatris Newsroom

Viatris Is Maintained at Underweight by Barclays

Dow JonesNov 8 14:29 ET

Viatris Analyst Ratings

BenzingaNov 8 14:19 ET

Barclays Maintains Viatris(VTRS.US) With Sell Rating, Raises Target Price to $12

Moomoo NewsNov 8 06:31 ET

Barclays Maintains Viatris(VTRS.US) With Sell Rating, Maintains Target Price $11

Moomoo NewsNov 6 03:33 ET

Barclays Maintains Viatris(VTRS.US) With Sell Rating, Maintains Target Price $11

Moomoo NewsOct 28 05:34 ET

Jefferies Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsOct 15 08:31 ET

Piper Sandler Maintains Viatris(VTRS.US) With Hold Rating, Maintains Target Price $13

Moomoo NewsSep 26 20:31 ET

Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma

Seeking AlphaSep 6 08:42 ET

Piper Sandler Maintains Viatris(VTRS.US) With Hold Rating, Maintains Target Price $13

Moomoo NewsJul 24 07:31 ET

Viatris Analyst Ratings

BenzingaJul 19 08:49 ET

Viatris Analyst Ratings

BenzingaMar 28 12:24 ET

Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $11

BenzingaNov 22, 2023 12:57 ET

Viatris Analyst Ratings

BenzingaNov 22, 2023 12:52 ET

B of A Securities Downgrades Viatris to Underperform, Announces $9 Price Target

BenzingaOct 23, 2023 07:21 ET

Viatris Analyst Ratings

BenzingaOct 23, 2023 07:20 ET

Piper Sandler Sticks to Their Hold Rating for Viatris (VTRS)

TipRanksAug 8, 2023 08:55 ET

Barclays Downgrades Viatris to Underweight, Announces $11 Price Target

BenzingaJun 23, 2023 05:47 ET

Barclays Downgrades Viatris to Equal-Weight, Lowers Price Target to $11

BenzingaApr 25, 2023 09:05 ET

Barclays Downgrades Viatris to Equal-Weight, Announces $11 Price Target

BenzingaApr 24, 2023 07:01 ET

Barclays Maintains Overweight on Viatris, Raises Price Target to $16

BenzingaFeb 28, 2023 09:30 ET